-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January 20, 2021 /--- In a recent study, scientists discovered a molecule that selectively kills specific breast cancer subtypes that are difficult to treat, potentially lead to a new treatment.
study was led by researchers at the RCSI School of Medicine and the University of Health Sciences and published in the latest issue of the journal Science Advance.
(Photo Source: www.pixabay.com) Three-negative breast cancer is a subtype of breast cancer, mainly treated with chemotherapy.
unfortunately, up to 70% of breast cancer patients are resistant to treatment.
researchers tested different molecules to see if they could selectively kill this type of breast cancer cell while preserving normal cells.
they found that a specific molecule, BAS-2, was able to do this.
"Our goal now is to develop small molecules into compounds that are more drug-like and to assess whether we can use new features to improve the effectiveness of treatment in patients," said dr. Tríona N? Chonghaile, a lecturer at RCSI and co-author of the study.
to better understand how the molecule kills cells, researchers have confirmed that it inhibits an enzyme called HDAC6.
using state-of-the-art mass spectrometrography to determine for the first time that HDAC6 played a key role in altering the energy of these cancer cells.
(Bioon.com) Source: Researchers discover potential new therapy for the original source of the breast cancer: Catríona M. Dowling et al, screening options reveal HDAC6 as novel regulator of glycolytic metabolism in triple-negative, Science Advances (2021). DOI: 10.1126/sciadv.abc4897